title: Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors.
abstract: OBJECTIVE
  To assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, and tolerability of the 24-h continuous intravenous (CIV) infusion of MK-0457, a novel pan-Aurora kinase inhibitor, in patients with advanced solid tumors and to determine the bioavailability of an oral dose of 100 mg MK-0457.
  
  
  METHODS
  MK-0457 was administered as a 24-h CIV infusion every 21 days. Dose escalation proceeded per toxicity criteria. A 100-mg oral dose was administered to seven patients 48 h prior to the CIV infusion dose of 64 mg/m(2)/h.
  
  
  RESULTS
  Twenty-seven patients received a total of 86 infusions of MK-0457. Dose-limiting toxicity at 96 mg/m(2)/h included grade 4 neutropenia and grade 3 herpes zoster. The MTD was identified as 64 mg/m(2)/h. The most common adverse events were nausea, vomiting, diarrhea, and fatigue. Pharmacokinetic analyses revealed that CIV infusion MK-0457 had an estimated mean terminal half-life of approximately 6.6-10.2 h and that end-of-infusion concentrations and mean AUCs were approximately dose proportional. The estimated mean oral bioavailability of MK-0457 was 7.9%. One patient with advanced ovarian cancer attained prolonged stable disease for 11 months.
  
  
  CONCLUSIONS
  MK-0457 was well tolerated in this schedule. Almost half the patients attained stable disease. Further development of this class of agents will likely occur in combination with other anti-cancer treatments.
authors.affiliation: University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, 3103 WIMR, 1111 Highland Avenue, Madison, WI 53705, USA. amt@medicine.wisc.edu
authors.forename: Anne M
authors.initials: AM
authors.lastname: Traynor
authors.forename: Maureen
authors.initials: M
authors.lastname: Hewitt
authors.forename: Glenn
authors.initials: G
authors.lastname: Liu
authors.forename: Keith T
authors.initials: KT
authors.lastname: Flaherty
authors.forename: Jason
authors.initials: J
authors.lastname: Clark
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Freedman
authors.forename: Boyd B
authors.initials: BB
authors.lastname: Scott
authors.forename: Ann Marie
authors.initials: AM
authors.lastname: Leighton
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Watson
authors.forename: Baiteng
authors.initials: B
authors.lastname: Zhao
authors.forename: Peter J
authors.initials: PJ
authors.lastname: O'Dwyer
authors.forename: George
authors.initials: G
authors.lastname: Wilding
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019540:Area Under Curve; D064127:Aurora Kinases; D001682:Biological Availability; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use* / Q000633:toxicity*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D016896:Treatment Outcome; D055815:Young Adult; D003521:Cyclopropanes; D011720:Pyrazoles; D011743:Pyrimidines
chemical_list: D064127:Aurora Kinases; D010879:Piperazines; D017346:Protein Serine-Threonine Kinases; C484810:tozasertib; D003521:Cyclopropanes; D011720:Pyrazoles; D011743:Pyrimidines
references.citation: Blood. 2007 Jan 15;109(2):500-2
references.pmid: 16990603
references.citation: Oncogene. 2005 Nov 10;24(49):7266-72
references.pmid: 16027732
references.citation: Mol Cancer Ther. 2006 Nov;5(11):2905-13
references.pmid: 17121938
references.citation: Oncogene. 2004 Nov 18;23(54):8720-30
references.pmid: 15480417
references.citation: Nat Med. 2004 Mar;10(3):262-7
references.pmid: 14981513
references.citation: Clin Cancer Res. 2008 Oct 1;14(19):6106-15
references.pmid: 18829489
references.citation: Nat Rev Cancer. 2004 Dec;4(12):927-36
references.pmid: 15573114
references.citation: Clin Cancer Res. 2008 Sep 1;14(17):5437-46
references.pmid: 18765535
references.citation: Hum Pathol. 2005 Dec;36(12):1281-8
references.pmid: 16311121
references.citation: Clin Cancer Res. 2009 Mar 15;15(6):2022-30
references.pmid: 19276280
references.citation: Oncologist. 2009 Aug;14(8):780-93
references.pmid: 19684075
references.citation: N Engl J Med. 2007 Jan 11;356(2):125-34
references.pmid: 17215530
references.citation: Chem Biol. 2008 Jun;15(6):552-62
references.pmid: 18559266
references.citation: Oncogene. 2008 May 22;27(23):3244-55
references.pmid: 18084327
references.citation: Clin Cancer Res. 2008 Mar 15;14(6):1639-48
references.pmid: 18347165
references.citation: Blood. 2008 Mar 1;111(5):2854-65
references.pmid: 18160664
references.citation: J Clin Oncol. 2009 Aug 10;27(23):3836-41
references.pmid: 19597027
references.citation: Endocr Relat Cancer. 2008 Jun;15(2):559-68
references.pmid: 18430894
references.citation: Clin Cancer Res. 1995 Dec;1(12):1455-61
references.pmid: 9815944
references.citation: J Med Chem. 2009 May 14;52(9):2629-51
references.pmid: 19320489
references.citation: Blood. 2008 Aug 1;112(3):793-804
references.pmid: 18505786
references.citation: Cancer Res. 2006 Aug 1;66(15):7668-77
references.pmid: 16885368
references.citation: Clin Cancer Res. 2009 Feb 1;15(3):840-50
references.pmid: 19188154